Formycon AG

Company info

ISIN DE000A1EWVY8
Country Deutschland

Upcoming Events

Event Functions

Add to favorite list Remove from favorites

Additional Functions

Nov 24

Formycon AG

Analysts’ Conference

Frankfurt am Main

Nov

2024

Formycon AG

Press Release – quarterly statement (call-date Q3)

Martinsried/Planegg

Past Events

Event Functions

Add to favorite list Remove from favorites

Additional Functions

Aug 24

Formycon AG

Publication half-yearly financial statements

Martinsried/Planegg

Jun 24

Formycon AG

Annual General Meeting

München

May 24

Formycon AG

Analysts’ Conference

Frankfurt am Main

May 24

Formycon AG

Press Release – quarterly financial report (call-date Q1)

Martinsried/Planegg

Apr 24

Formycon AG

Publication of Annual Report

Martinsried/Planegg

Nov 23

Formycon AG

Analysts’ Conference

Frankfurt am Main

Nov 23

Formycon AG

Press Release – quarterly financial report (call-date Q3)

Martinsried/Planegg

Aug 23

Formycon AG

Publication half-yearly financial statements

Martinsried/Planegg

Jul 23

Formycon AG

Annual General Meeting

Munich

May 23

Formycon AG

Press Release – quarterly financial report (call-date Q1)

Martinsried/Planegg

May 23

Formycon AG

Analysts’ Conference

Frankfurt am Main

Apr 23

Formycon AG

Publication of Annual Report

Martinsried/Planegg

Nov 22

Formycon AG

Analysts’ Conference

Frankfurt/Main

Nov

2022

Formycon AG

Press Release – quarterly statement (call-date Q3)

Martinsried/Planegg

Oct 22

Formycon AG

Publication half-yearly financial statements

Martinsried/Planegg

Jun 22

Formycon AG

Annual General Meeting

Munich

Jun 22

Formycon AG

Press Release – quarterly statement (call-date Q1)

Martinsried/Planegg

May 22

Formycon AG

Analysts’ Conference

Frankfurt/Main

May 22

Formycon AG

Publication of Annual Report

Martinsried/Planegg

Nov 21

Formycon AG

Publication quarterly statement (call-date Q3)

Martinsried / Planegg

Sep 21

Formycon AG

Annual General Meeting

Munich

Sep 21

Formycon AG

Publication half-yearly financial statements

Martinsried / Planegg

Jun 21

Formycon AG

Publication quarterly statement (call-date Q1)

Martinsried / Planegg

May 21

Formycon AG

Publication of Annual Report

Martinsried / Planegg

Dec 20

Formycon AG

Annual General Meeting

Munich

Nov 20

Formycon AG

Analysts’ Conference

Frankfurt / Main

Nov 20

Formycon AG

Press Release – quarterly statement (call-date Q3)

Martinsried / Planegg

Sep 20

Formycon AG

Publication half-yearly financial statements

Martinsried / Planegg

Jun 20

Formycon AG

Press Release – quarterly statement (call-date Q1)

Martinsried / Planegg

May 20

Formycon AG

Publication of Annual Report

Martinsried / Planegg

Mar 20

Formycon AG

Analysts’ Conference

Dreieich-Götzenhain

Sep

2019

Formycon AG

Publication half-yearly financial statements

Jun 19

Formycon AG

Annual General Meeting

Planegg

May 19

Formycon AG

Publication of Annual Report

Sep

2018

Formycon AG

Publication half-yearly financial statements

Martinsried/Planegg

Jun 18

Formycon AG

Annual General Meeting

Planegg

Jun

2018

Formycon AG

Publication of Annual Report

Martinsried/Planegg

Sep

2017

Formycon AG

Publication half-yearly financial statements

Jun 17

Formycon AG

Annual General Meeting

Jun

2017

Formycon AG

Publication of Annual Report

Latest News

News Functions

Add to favorite list Remove from favorites

Additional Functions

4 November 2024

06:30 Corporate

Formycon AG

Corporate

Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange

16 October 2024

06:50 Corporate

Formycon AG

Corporate

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D

30 September 2024

07:30 Corporate

Formycon AG

Corporate

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)

27 September 2024

21:56 Ad-hoc

Formycon AG

Ad-hoc

FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)

09:00 Corporate

Formycon AG

Corporate

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases

17 September 2024

06:50 Corporate

Formycon AG

Corporate

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna

More News

Latest Reports

News Functions

Add to favorite list Remove from favorites

Additional Functions

22 October 2024

29 April 2024

30 August 2023

More Reports

Latest Research

News Functions

Add to favorite list Remove from favorites

Additional Functions

1 October 2024

19 August 2024

13 June 2024

21 August 2023

23 September 2022

7 September 2022

More Research

Latest Webcasts

No Webcasts found